| __timestamp | Perrigo Company plc | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2613100000 | 5903000 |
| Thursday, January 1, 2015 | 2891500000 | 2762000 |
| Friday, January 1, 2016 | 3228800000 | 1114000 |
| Sunday, January 1, 2017 | 2966700000 | 25573000 |
| Monday, January 1, 2018 | 2900200000 | 6000000 |
| Tuesday, January 1, 2019 | 3064100000 | 38845000 |
| Wednesday, January 1, 2020 | 3248100000 | 50523000 |
| Friday, January 1, 2021 | 2722500000 | 75463000 |
| Saturday, January 1, 2022 | 2996200000 | 105767000 |
| Sunday, January 1, 2023 | 2975200000 | 167512000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. Perrigo Company plc, a global leader in over-the-counter health products, and Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, present contrasting cost of revenue trends from 2014 to 2023. Perrigo's cost of revenue has shown a relatively stable trajectory, peaking in 2020 with a 24% increase from 2014, before slightly declining by 8% in 2021. In contrast, Xenon Pharmaceuticals has experienced a dramatic rise, with costs surging by over 2,700% from 2014 to 2023. This stark difference highlights the varying operational scales and market strategies of these companies. While Perrigo maintains a steady course, Xenon's growth reflects its aggressive expansion and investment in research and development. These insights underscore the diverse financial landscapes within the pharmaceutical sector, offering a glimpse into the strategic priorities of these two distinct entities.
Cost of Revenue: Key Insights for Novo Nordisk A/S and Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Perrigo Company plc's Expenses
Intra-Cellular Therapies, Inc. vs Xenon Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: BioMarin Pharmaceutical Inc. vs Perrigo Company plc
Halozyme Therapeutics, Inc. vs Xenon Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Halozyme Therapeutics, Inc. and Perrigo Company plc
Cost Insights: Breaking Down Corcept Therapeutics Incorporated and Perrigo Company plc's Expenses
Cost of Revenue Comparison: Ionis Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
Perrigo Company plc vs Vericel Corporation: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Perrigo Company plc vs Dyne Therapeutics, Inc.
Xenon Pharmaceuticals Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Xenon Pharmaceuticals Inc. vs MiMedx Group, Inc.